{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:40:39Z","timestamp":1772134839819,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"21","license":[{"start":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T00:00:00Z","timestamp":1520380800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1038\/s41388-018-0157-8","type":"journal-article","created":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T02:25:14Z","timestamp":1520216714000},"page":"2837-2849","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Targeting PFKFB3 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6928-4027","authenticated-orcid":false,"given":"Yu","family":"Zhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luo","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huapeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sixuan","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huihui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongfa","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaoyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,7]]},"reference":[{"key":"157_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/nrclinonc.2016.139","volume":"14","author":"G Rosti","year":"2016","unstructured":"Rosti G, Castagnetti F, Gugliotta G, Baccarani M. Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? Nat Rev Clin Oncol. 2016;14:141\u201354.","journal-title":"Nat Rev Clin Oncol"},{"key":"157_CR2","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/leu.2017.9","volume":"31","author":"C Sch\u00fctz","year":"2017","unstructured":"Sch\u00fctz C, Inselmann S, Sausslele S, Dietz C, Mu\u0308 Ller M, Eigendorff E, et al. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Leukemia. 2017;31:829\u201336.","journal-title":"Leukemia"},{"key":"157_CR3","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","volume":"129","author":"TL Holyoake","year":"2017","unstructured":"Holyoake TL, Vetrie D. The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood . 2017;129:1595\u2013606.","journal-title":"Blood"},{"key":"157_CR4","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1182\/blood-2016-08-693630","volume":"129","author":"J Gotlib","year":"2017","unstructured":"Gotlib J. How I treat atypical chronic myeloid leukemia. Blood. 2017;129:838\u201345.","journal-title":"Blood"},{"key":"157_CR5","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/leu.2011.66","volume":"25","author":"LS Steelman","year":"2011","unstructured":"Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, B\u00e4secke J, et al. Roles of the Ras\/Raf\/MEK\/ERK pathway in leukemia therapy. Leukemia. 2011;25:1080\u201394.","journal-title":"Leukemia"},{"key":"157_CR6","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3324\/haematol.2013.098442","volume":"99","author":"S Bibi","year":"2014","unstructured":"Bibi S, Arslanhan MD, Langenfeld F, Jeanningros S, Cerny-Reiterer S, Hadzijusufovic E, et al. Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy. Haematologica . 2014;99:417\u201329.","journal-title":"Haematologica"},{"key":"157_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1756-8722-4-6","volume":"4","author":"H Quentmeier","year":"2011","unstructured":"Quentmeier H, Eberth S, Romani J, Zaborski M, Drexler HG. BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. J Hematol Oncol. 2011;4:6.","journal-title":"J Hematol Oncol"},{"key":"157_CR8","doi-asserted-by":"publisher","DOI":"10.4161\/jkst.25256","volume":"2","author":"O Yamada","year":"2013","unstructured":"Yamada O, Kawauchi K. The role of the JAK-STAT pathway and related signal cascades in telomerase activation during the development of hematologic malignancies. Jak-Stat. 2013;2:e25256.","journal-title":"Jak-Stat"},{"key":"157_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.4161\/jkst.20006","volume":"1","author":"M Bar-Natan","year":"2012","unstructured":"Bar-Natan M, Nelson EA, Xiang M, Frank DA. STAT signaling in the pathogenesis and treatment of myeloid malignancies. Jak-Stat. 2012;1:55\u201364.","journal-title":"Jak-Stat"},{"issue":"10","key":"157_CR10","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1038\/leu.2017.87","volume":"31","author":"H Zhou","year":"2017","unstructured":"Zhou H, Mak PY, Mu H, Mak DH, Zeng Z, Cortes J et al. Combined inhibition of \u03b2-catenin and Bcr\u2013Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo. Leukemia. 2017. \n                    https:\/\/doi.org\/10.1038\/leu.2017.87\n                    \n                  .","journal-title":"Leukemia"},{"key":"157_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1756-8722-1-15","volume":"1","author":"S Cang","year":"2008","unstructured":"Cang S, Liu D. P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia. J Hematol Oncol. 2008;1:15.","journal-title":"J Hematol Oncol"},{"key":"157_CR12","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1038\/leu.2017.72","volume":"31","author":"SH Han","year":"2017","unstructured":"Han SH, Kim S-H, Kim H-J, Lee Y, Choi S-Y, Park G, et al. Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia. Leukemia. 2017;31:1532\u20139.","journal-title":"Leukemia"},{"key":"157_CR13","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/leu.2016.231","volume":"31","author":"Z Chen","year":"2017","unstructured":"Chen Z, Shao C, Wang W, Zuo Z, Mou X, Hu SJ, et al. Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Leukemia. 2017;31:585\u201392.","journal-title":"Leukemia"},{"key":"157_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/leu.2016.179","volume":"31","author":"L Eadie","year":"2016","unstructured":"Eadie L, Dang P, Saunders V, Yeung D, Osborn M, Grigg A, et al. The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment. Leukemia. 2016;31:75\u201382.","journal-title":"Leukemia"},{"key":"157_CR15","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1038\/leu.2016.51","volume":"30","author":"M Wagle","year":"2016","unstructured":"Wagle M, Eiring AM, Wongchenko M, Lu S, Guan Y, Wang Y, et al. A role for FOXO1 in BCR\u2013ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Leukemia. 2016;30:1493\u2013501.","journal-title":"Leukemia"},{"key":"157_CR16","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/1873-3468.12057","volume":"590","author":"CR Lee","year":"2016","unstructured":"Lee C-R, Kang J-A, Kim H-E, Choi Y, Yang T, Park S-G. Secretion of IL-1\u03b2 from imatinib-resistant chronic myeloid leukemia cells contributes to BCR - ABL mutation-independent imatinib resistance. FEBS Lett. 2016;590:358\u201368.","journal-title":"FEBS Lett"},{"key":"157_CR17","doi-asserted-by":"publisher","first-page":"6181","DOI":"10.1158\/1078-0432.CCR-08-0461","volume":"14","author":"S Okabe","year":"2008","unstructured":"Okabe S, Tauchi T, Ohyashiki K. Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells. Clin Cancer Res. 2008;14:6181\u20136.","journal-title":"Clin Cancer Res"},{"key":"157_CR18","doi-asserted-by":"publisher","first-page":"21446","DOI":"10.1074\/jbc.M109.090043","volume":"285","author":"T Pene-Dumitrescu","year":"2010","unstructured":"Pene-Dumitrescu T, Smithgall TE. Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner. J Biol Chem. 2010;285:21446\u201357.","journal-title":"J Biol Chem"},{"key":"157_CR19","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1756-8722-6-54","volume":"6","author":"K Sweet","year":"2013","unstructured":"Sweet K, Zhang L, Pinilla-Ibarz J. Biomarkers for determining the prognosis in chronic myelogenous leukemia. J Hematol Oncol. 2013;6:54.","journal-title":"J Hematol Oncol"},{"key":"157_CR20","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.1172\/JCI66129","volume":"124","author":"Y Chen","year":"2014","unstructured":"Chen Y, Peng C, Abraham SA, Shan Y, Guo Z, Desouza N, et al. Arachidonate 15-lipoxygenase is required for chronic myeloid leukemia stem cell survival. J Clin Investig. 2014;124:3847\u201362.","journal-title":"J Clin Investig"},{"key":"157_CR21","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/ng.389","volume":"41","author":"Y Chen","year":"2009","unstructured":"Chen Y, Hu Y, Zhang H, Peng C, Li S. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet. 2009;41:783\u201392.","journal-title":"Nat Genet"},{"key":"157_CR22","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1200\/JCO.2009.23.4732","volume":"28","author":"T Haferlach","year":"2010","unstructured":"Haferlach T, Kohlmann A, Wieczorek L, Basso G, Te Kronnie G, B\u00e9n\u00e9 MC, et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the international microarray innovations in leukemia study group. J Clin Oncol. 2010;28:2529\u201337.","journal-title":"J Clin Oncol"},{"key":"157_CR23","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.ccell.2016.10.006","volume":"30","author":"AR Cantelmo","year":"2016","unstructured":"Cantelmo AR, Conradi LC, Brajic A, Goveia J, Kalucka J, Pircher A, et al. Inhibition of the glycolytic activator PFKFB3 in endothelium induces tumor vessel normalization, impairs metastasis, and improves chemotherapy. Cancer Cell. 2016;30:968\u201385.","journal-title":"Cancer Cell"},{"key":"157_CR24","first-page":"1","volume":"5","author":"T Yamamoto","year":"2014","unstructured":"Yamamoto T, Takano N, Ishiwata K, Ohmura M, Nagahata Y, Matsuura T, et al. Reduced methylation of PFKFB3 in cancer cells shunts glucose towards the pentose phosphate pathway. Nat Commun. 2014;5:1\u201316.","journal-title":"Nat Commun."},{"key":"157_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12240","volume":"7","author":"B Cruys","year":"2016","unstructured":"Cruys B, Wong BW, Kuchnio A, Verdegem D, Cantelmo AR, Conradi L-C, et al. Glycolytic regulation of cell rearrangement in angiogenesis. Nat Commun. 2016;7:12240.","journal-title":"Nat Commun"},{"key":"157_CR26","doi-asserted-by":"publisher","first-page":"382","DOI":"10.4161\/auto.27345","volume":"10","author":"Z Yang","year":"2014","unstructured":"Yang Z, Goronzy JJ, Weyand CM. The glycolytic enzyme PFKFB3\/phosphofructokinase regulates autophagy. Autophagy. 2014;10:382.","journal-title":"Autophagy"},{"key":"157_CR27","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/ncb3231","volume":"17","author":"E Dom\u00e9nech","year":"2015","unstructured":"Dom\u00e9nech E, Maestre C, Esteban-Mart\u00ednez L, Partida D, Pascual R, Fern\u00e1ndez-Miranda G, et al. AMPK and PFKFB3 mediate glycolysis and survival in response to mitophagy during mitotic arrest. Nat Cell Biol. 2015;17:1304\u201316.","journal-title":"Nat Cell Biol"},{"key":"157_CR28","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.cell.2013.06.037","volume":"154","author":"K Bock De","year":"2013","unstructured":"De Bock K, Georgiadou M, Schoors S, Kuchnio A, Wong BW, Cantelmo AR, et al. Role of PFKFB3-driven glycolysis in vessel sprouting. Cell. 2013;154:651\u201363.","journal-title":"Cell"},{"key":"157_CR29","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-016-0360-4","volume":"9","author":"S Qian","year":"2016","unstructured":"Qian S, Li J, Hong M, Zhu Y, Zhao H, Xie Y, et al. TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and 3 acute myeloid leukemia. J Hematol Oncol. 2016;9:128.","journal-title":"J Hematol Oncol."},{"key":"157_CR30","doi-asserted-by":"publisher","first-page":"12643","DOI":"10.1007\/s13277-016-5179-7","volume":"37","author":"DM Oaxaca","year":"2016","unstructured":"Oaxaca DM, Yang-Reid SA, Ross JA, Rodriguez G, Staniswalis JG, Kirken RA. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment. Tumor Biol. 2016;37:12643\u201354.","journal-title":"Tumor Biol"},{"key":"157_CR31","doi-asserted-by":"publisher","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","volume":"174","author":"LD Shultz","year":"2005","unstructured":"Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, et al. Human lymphoid and myeloid cell development in NOD\/LtSz-scid IL2R null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005;174:6477\u201389.","journal-title":"J Immunol"},{"key":"157_CR32","first-page":"663","volume":"5","author":"D Ray","year":"1990","unstructured":"Ray D, Culine S, Tavitain A, Moreau-Gachelin F. The human homologue of the putative proto-oncogene Spi-1: characterization and expression in tumors. Oncogene. 1990;5:663\u20138.","journal-title":"Oncogene"},{"key":"157_CR33","doi-asserted-by":"publisher","first-page":"8705","DOI":"10.1073\/pnas.96.15.8705","volume":"96","author":"P Zhang","year":"1999","unstructured":"Zhang P, Behre G, Pan J, Iwama A, Wara-aswapati N, Radomska HS, et al. Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1. Proc Natl Acad Sci USA. 1999;96:8705\u201310.","journal-title":"Proc Natl Acad Sci USA"},{"key":"157_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-12-152","volume":"12","author":"S Ganapathy-Kanniappan","year":"2013","unstructured":"Ganapathy-Kanniappan S, Geschwind, J-FH. Tumor glycolysis as a target for cancer therapy: progress and prospects. Mol Cancer. 2013;12:152","journal-title":"Mol Cancer"},{"issue":"1","key":"157_CR35","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1158\/1535-7163.MCT-07-0482","volume":"7","author":"B. Clem","year":"2008","unstructured":"Clem B, Telang S, Clem A, Yalcin A, Meier J, Simmons A et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Therapeut. 2008. \n                    https:\/\/doi.org\/10.1158\/1535-7163.MCT-07-0482\n                    \n                  .","journal-title":"Molecular Cancer Therapeutics"},{"key":"157_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.292","volume":"5","author":"A Yalcin","year":"2014","unstructured":"Yalcin A, Clem BF, Imbert-Fernandez Y, Ozcan SC, Peker S, O\u2019Neal J, et al. 6-Phosphofructo-2-kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1-mediated phosphorylation ofp27. Cell Death Dis. 2014;5:e1337.","journal-title":"Cell Death Dis"},{"key":"157_CR37","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ajpath.2013.07.035","volume":"184","author":"HA Coller","year":"2014","unstructured":"Coller HA. Is cancer a metabolic disease? Am J Pathol. 2014;184:4\u201317.","journal-title":"Am J Pathol"},{"key":"157_CR38","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1158\/1535-7163.MCT-13-0097","volume":"12","author":"BF Clem","year":"2013","unstructured":"Clem BF, O\u2019Neal J, Tapolsky G, Clem AL, Imbert-Fernandez Y, Kerr DA, et al. Targeting 6-Phosphofructo-2-Kinase (PFKFB3) as a therapeutic strategy against cancer. Mol Cancer Ther. 2013;12:1461\u201370.","journal-title":"Mol Cancer Ther"},{"key":"157_CR39","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.cell.2012.04.026","volume":"149","author":"T Li","year":"2012","unstructured":"Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y, et al. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell. 2012;149:1269\u201383.","journal-title":"Cell"},{"key":"157_CR40","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.4161\/cc.22778","volume":"11","author":"OC Rodriguez","year":"2012","unstructured":"Rodriguez OC, Choudhury S, Kolukula V, Vietsch EE, Catania J, Preet A, et al. Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy. Cell Cycle. 2012;11:4436\u201346.","journal-title":"Cell Cycle"},{"key":"157_CR41","doi-asserted-by":"publisher","first-page":"867","DOI":"10.4161\/cc.23911","volume":"12","author":"SH Moon","year":"2013","unstructured":"Moon SH, Prives C. Mutant p53 succumbs to starvation. Cell Cycle. 2013;12:867\u20138.","journal-title":"Cell Cycle"},{"key":"157_CR42","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.bbrc.2017.01.178","volume":"484","author":"A Yalcin","year":"2017","unstructured":"Yalcin A, Solakoglu TH, Ozcan SC, Guzel S, Peker S, Celikler S, et al. 6-phosphofructo-2-kinase\/fructose 2,6-bisphosphatase-3 is required for transforming growth factor \u03b21-enhanced invasion of Panc1 cells in vitro. Biochem Biophys Res Commun. 2017;484:687\u201393.","journal-title":"Biochem Biophys Res Commun"},{"key":"157_CR43","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1126\/science.288.5470.1439","volume":"288","author":"RP DeKoter","year":"2000","unstructured":"DeKoter RP. Regulation of B lymphocyte and macrophage development by graded expression of PU.1. Science. 2000;288:1439\u201341.","journal-title":"Science"},{"key":"157_CR44","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1172\/JCI92504","volume":"127","author":"I Antony-Debr\u00e9","year":"2017","unstructured":"Antony-Debr\u00e9 I, Paul A, Leite J, Mitchell K, Kim HM, Carvajal LA, et al. Pharmacological inhibition of the transcription factor PU.1 in leukemia. J Clin Investig. 2017;127:4297\u20134313.","journal-title":"J Clin Investig."}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0157-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0157-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-018-0157-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:10:32Z","timestamp":1684602632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-018-0157-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,7]]},"references-count":44,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["157"],"URL":"https:\/\/doi.org\/10.1038\/s41388-018-0157-8","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732811511.793583303","asserted-by":"object"}]},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,7]]},"assertion":[{"value":"4 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}